TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

Adoptive immunotherapy with T lymphocytes expressing transgenic T-cell receptors (TCRs) has shown significant clinical efficacy in various malignant diseases. However, concurrent expression of endogenous and transgenic TCRs in one and the same T cell may impair efficacy and cause safety problems owing to mispairings. The most elegant approach to address these issues is the complete shutoff of the endogenous receptor chains by genome editing. To this end, we designed TCR-α and TCR-β-specific pairs of transcription activator-like effector nucleases (TALENs). TALENs were delivered into T cells using an optimized messenger RNA-electroporation protocol. Based thereon, we obtained precise and highly efficient knockout (KO) in Jurkat (TCR-α: 59.7±4.0%, TCR-β: 37.4±7.3%) as well as primary T cells (TCR-α: 58.0±15.0%, TCR-β: 41.0±17.6%). Moreover, a successive KO strategy for the endogenous TCR chains combined with subsequent transduction of the respective chains of an Influenza virus-specific model TCR led to complete reprogramming of T cells with strongly improved expression and functionality of transgenic TCRs. In conclusion, we have developed novel means for the efficient genome editing in primary T lymphocytes.

[1]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[2]  Volker Brendel,et al.  TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction , 2012, Nucleic Acids Res..

[3]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[4]  A. Amir,et al.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity , 2010, Proceedings of the National Academy of Sciences.

[5]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[6]  R. Hagedoorn,et al.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. , 2007, Blood.

[7]  Kari N. Haley,et al.  Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells. , 2010, Human gene therapy.

[8]  C. von Kalle,et al.  Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk , 2011, Hepatology.

[9]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Han-Woong Lee,et al.  Knockout mice created by TALEN-mediated gene targeting , 2013, Nature Biotechnology.

[11]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[12]  S. Rosenberg,et al.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. , 2007, Cancer research.

[13]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[14]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[15]  Hans A. Kestler,et al.  Chromosomal Integration of Adenoviral Vector DNA In Vivo , 2010, Journal of Virology.

[16]  M. Kalos.  Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses , 2011, Cancer Immunology, Immunotherapy.

[17]  G. Ciliberto,et al.  Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.

[18]  W. Uckert,et al.  Minimal Amino Acid Exchange in Human TCR Constant Regions Fosters Improved Function of TCR Gene-Modified T Cells , 2010, The Journal of Immunology.

[19]  R. Morgan,et al.  Genetic engineering with T cell receptors. , 2012, Advanced drug delivery reviews.

[20]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[21]  Daniel G. Miller,et al.  Chromosomal effects of adeno-associated virus vector integration , 2002, Nature Genetics.

[22]  B. Fehse,et al.  Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis , 2010, Gene Therapy.

[23]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Gunnar Kvalheim,et al.  Transiently redirected T cells for adoptive transfer. , 2011, Cytotherapy.

[25]  B. Fehse,et al.  A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. , 2008, Molecular Therapy.

[26]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[27]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[28]  R. Morgan,et al.  Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition , 2010, The Journal of Immunology.

[29]  Neville E Sanjana,et al.  A transcription activator-like effector toolbox for genome engineering , 2012, Nature Protocols.

[30]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[31]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[32]  Jeffrey C. Miller,et al.  An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.

[33]  H. Ikeda,et al.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. , 2009, Cancer research.

[34]  E. Morris,et al.  Immunotherapy with gene-modified T cells: limiting side effects provides new challenges , 2013, Gene Therapy.

[35]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[36]  M. Hansmann,et al.  Resistance of mature T cells to oncogene transformation. , 2008, Blood.

[37]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[38]  C. Meijer,et al.  Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. , 2006, Clinical immunology.

[39]  N. Kröger,et al.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy , 2013, Human vaccines & immunotherapeutics.

[40]  F. Bushman,et al.  Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.

[41]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[42]  A. Zander,et al.  Highly‐efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin , 1998, British journal of haematology.

[43]  Nieng Yan,et al.  Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors , 2012, Science.

[44]  G. Schuler,et al.  Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. , 2013, Methods in molecular biology.